Skip to main content
Clinical Trials/NCT01083017
NCT01083017
Completed
Not Applicable

Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.

University Hospital, Geneva3 sites in 1 country74 target enrollmentApril 2011

Overview

Phase
Not Applicable
Intervention
chlorthalidone
Conditions
Hypertension
Sponsor
University Hospital, Geneva
Enrollment
74
Locations
3
Primary Endpoint
blood pressure control
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
May 2017
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Georg EHRET

intern

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • informed consent
  • resistant hypertension at the moment of inclusion
  • 18 years or more, both sexes are included
  • women at reproductive age: consenting to use oral contraception

Exclusion Criteria

  • patients mentally impaired or unable to give informed consent
  • patients speaking only a foreign language other than French, German, or English
  • patients living far away, making the study visits not practical

Arms & Interventions

chlorthalidone

Intervention: chlorthalidone

motivational invervention

motivational interview(s) vs. repeated calls vs. no particular intervention

Intervention: motivational intervention for non-compliant individuals

standardized anti-hypertensive treatment

Intervention: standardized anti-hypertensive treatment

Outcomes

Primary Outcomes

blood pressure control

Time Frame: at 12 weeks after initiation of standard treatment

Secondary Outcomes

  • cardiovascular morbidity and mortality(5 years)

Study Sites (3)

Loading locations...

Similar Trials